ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2009
Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation.Drug and alcohol dependence · 2022Pooled it
- Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.Pharmacogenetics and genomics · 2013Trial
- Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes.The pharmacogenomics journal · 2012Trial
- Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Cholinergic Receptor Nicotinic Beta 2 Subunit Promotes the Peritoneal Disseminating Metastasis of Colorectal Cancer.Cancers · 2025Article
- The 2022 Ferno Award Address: CrEATE, an Efficient Crossover Evaluation of Addiction Treatment Efficacy.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Article
- Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells.Oncogene · 2021Article
- Network analysis of the genomic basis of the placebo effect.JCI insight · 2017Article
- Associations of rare nicotinic cholinergic receptor gene variants to nicotine and alcohol dependence.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2016Article
- A review of pharmacogenetic studies of substance-related disorders.Drug and alcohol dependence · 2015Review
- Nicotinic receptor contributions to smoking: insights from human studies and animal models.Current addiction reports · 2015Article
- CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy.Frontiers in genetics · 2015Article
- Nicotine withdrawal.Current topics in behavioral neurosciences · 2015Review
- Nominal association with CHRNA4 variants and nicotine dependence.Genes, brain, and behavior · 2013Article
- Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.Human genetics · 2012Article
- Biomarkers to optimize the treatment of nicotine dependence.Biomarkers in medicine · 2011Review
- Serum NPY and BNDF response to a behavioral stressor in alcohol-dependent and healthy control participants.Psychopharmacology · 2011Article
- Associations of nicotine intake measures with CHRN genes in Finnish smokers.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2011Article
- Relapse prevention for addictive behaviors.Substance abuse treatment, prevention, and policy · 2011Review
- The galanin receptor 1 gene associates with tobacco craving in smokers seeking cessation treatment.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Genes coding for nicotinic acetylcholine receptors may influence response to nicotine replacement therapy for smoking cessation. We examined the association of a 3' untranslated region polymorphism (rs2072661) in the nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene with quitting success in response to nicotine versus placebo patch during a short-term test of patch effects. In a within-subjects cross-over design, smokers of European descent (n = 156) received 21 mg nicotine and placebo patch in counter-balanced order, during two separate 5-day simulated quit attempts, each preceded by a week of ad libitum smoking. Abstinence was assessed daily by CO < 5 ppm. Smokers with the CHRNB2 GG genotype had more days of abstinence during the nicotine versus placebo patch week compared with those with the AG or AA genotypes (P < 0.01). Moreover, nicotine patch increased the probability of quitting on the target quit day, quitting anytime during the patch week, and avoiding relapse among those with the GG genotype but not the AA/AG genotypes, although the nicotine x genotype interaction was significant only for quitting on the target quit day (P < 0.05). Regardless of patch condition, quitting on the target quit day was more likely in those with the GG genotype versus AA/AG genotypes (P < 0.05). Genetic associations were not observed for craving or withdrawal responses to nicotine versus placebo patch. These findings are consistent with previous evidence of association of this variant with smoking cessation and suggest that polymorphisms in the nicotinic acetylcholine receptor beta2 subunit gene may influence therapeutic responsiveness to cessation medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.